The Biotech space has seen a lot of price action in both directions over the past several months. As such, there is no surprise that options premiums in that corner of the market have become a bit elevated.
There’s a setup I’ve spotted that offers us a good opportunity to fade these premiums as the sector pauses to digest recent activity.